Novartis 4th-qtr sales and earnings beat expectation

24 January 2018

Swiss pharma giant Novartis (NOVN: VX) pleased investors this morning with its fourth-quarter and full-year 2017 financial results, posting sales growth of 5% to $12.9 billion (+2% at constant exchange) for the last quarter, beating analysts’ estimate of $12.7 billion.

Earnings excluding special items climbed 7% (+5% CC) to $3.2 billion in the fourth quarter, compared with the $3.1 billion average of analysts’ estimates compiled by Bloomberg, with the news sending Novartis’ shares 2.56% higher to 85.74 Swiss francs. Earnings per share were up 8% (+6% cc) at $1.21.

2017 full-year sales rose 1% to reach $49.11 billion (+2% at cc). Operating income was up 4% (+7% cc) to $8.63 billion, with net income at $7.70 billion, up 15% (+14% cc). Earnings per share rose 16% (+14% cc) to $3.28.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK